The Burrill Report


The Burrill Report (July 30, 2012): Building a Better Cancer Drug (.MP3,19.83 Mb)

New cancer therapies are expanding an ever-more powerful arsenal of targeted drugs against variations of the disease, but problems of toxicity often limit their use. Genzyme founder Sheridan Snyder and Chris Liang, who played a key role in the development of the cancer drug Sutent, launched Xcovery in 2006 with the hope of building better molecules. The company’s lead therapeutic, now in early-stage clinical testing, is essentially a safer version of Sutent. We spoke to Samuel Broder, senior Scientific and Clinical Strategist for Xcovery, about the challenges toxicity poses in cancer therapies, how this limits not only dosing but combination therapies, and how Xcovery’s approach to altering existing drugs can make them safer or enhance other properties.

July 27, 2012
http://www.burrillreport.com/article-building_a_better_cancer_drug.html